Effect of renal function on high-density lipoprotein particles in patients with coronary heart disease

Long Jieni¹, Xue Yazhi¹, Zeng Xiaorong¹, Liu Dan², Ma Yusheng², Rao Jiahuan², Zhang Bin¹, Li Li¹* and Guo Zhigang²*

Abstract

Background: Although renal insufficiency and dyslipidemia are known to be closely associated, the effect of kidney function on the size and clinical value of high-density lipoprotein (HDL) particles remains largely unknown, especially in patients with coronary heart disease.

Methods: A total of 419 coronary heart disease patients and 105 non-coronary heart disease patients were included. HDL particle size, represented by HDL-C/apoA-I, was compared between groups stratified by estimated glomerular filtration rate (eGFR) and Gensini scores using standard Student’s t test and one-way ANOVA. Pearson’s correlation test was performed to analyze the association between eGFR and HDL-C/apoA-I in patients with coronary heart disease. The relationship between HDL particle size and the occurrence of coronary heart disease was explored using Univariate logistic regression analysis.

Results: In patients with coronary heart disease, between-group analysis revealed that HDL-C/apoA-I increased as eGFR declined, and significance appeared as eGFR declined to under 60 ml/min·1.73 m² (P < 0.001), and Pearson’s correlation test also confirmed an inverse correlation between eGFR and HDL-C/apoA-I levels in coronary heart disease patients. When stratified by Gensini scores, in coronary heart disease patients with eGFR ≥ 90 mL/(min·1.73 m²), those with higher Gensini scores had smaller HDL-C/apoA-I. However, with or without kidney insufficiency, smaller HDL-C/apoA-I was associated with a higher occurrence of coronary heart disease (P < 0.05).

Conclusion: With the presence of renal insufficiency, HDL-C/apoA1 was higher in patients with coronary heart disease. Lower HDL-C/apoA1 was still associated with a higher occurrence of coronary heart disease, but the original association between lower HDL-C/apoA1 and more severe coronary artery stenosis was lost in patients with renal insufficiency.

Keywords: Coronary heart disease, Renal insufficiency, HDL-C/apoA-I, HDL particles

Background

High-density lipoprotein (HDL) has been acknowledged as a protective factor for cardiovascular disease, as there is unequivocal evidence of the inverse association between the HDL-C level and the occurrence and mortality of cardiovascular disease [1]. However, in recent years, several clinical trials aiming to increase plasma high-density lipoprotein cholesterol (HDL-C)
concentrations, such as the ILLUMINATE study, AIM-HIGH study and HPS2-THRIVE study, have failed to consistently obtain satisfying results, indicating that HDL particles and HDL function may play a more important role than the HDL-C level in plasma [2–4]. HDL lipoproteins are in fact not intact particles, but consisting of components that differ in composition and function, yet the exact relationship between HDL particles, HDL function and cardiovascular diseases remains unclear.

Dyslipidemia is also closely associated with renal insufficiency. Chronic kidney disease is believed to be related to systemic inflammatory responses, and in recent years, evidence has shown that dyslipidemia may contribute to the development of kidney dysfunction [5]. Alterations in the distribution and quality of lipoproteins have been reported in multiple studies, but the findings appear to be inconsistent and even contradictory due to the complex nature of lipid metabolism. Large, mature HDL particles are generally considered to be anti-inflammatory and cardiovascular protective, and recently, studies have reported decreased amounts of larger HDL particles in patients with end stage kidney disease (ESRD) [6].

Due to the complicated compositions of HDL, nuclear magnetic resonance imaging (NMRI) is usually used to measure the diameter of HDL particles [7]; however, this specific method can be difficult to apply. In 2013, in a study based on the Women’s Health study, the ratio of HDL-C to apolipoprotein A-I (apoA-I) was discovered to be linearly correlated with actual HDL diameter measured by NMRI, indicating that HDL-C/apoA-I can serve as a reliable biomarker representing HDL particle size [8].

In this study, the potential effect of kidney function on the value and size of HDL, represented by HDL-C/apoA-I, was explored in patients with coronary heart disease.

Methods

Study populations

A total of 524 inpatients met the following inclusion criteria were enrolled by simple random sampling: (1) Hospitalized and underwent coronary angiography for the first time between January 2013 and December 2018; (2) No lipid-lowering medications in 3 months prior to hospitalization; (3) All necessary data were available. Exclusion criteria: (1) Previous history of percutaneous coronary intervention or coronary artery bypass grafting; (2) Acute kidney injury or on dialysis; (3) Other diseases that might cause unstable hemodynamics such as severe infectious diseases, hematologic diseases and progressive tumors. The Study was approved by and carried out in accordance with institutional review board of Nanfang Hospital of Southern Medical University, and informed consent was obtained from participants/legal guardians of participants involved in the study.

Laboratory measurement and calculation

Fasting venous blood samples were collected at the time of admission and stored at −70 °C after centrifugation and tested with standard measurements in the laboratory of Nanfang Hospital. CR (Creatinine), Cys-C (Cystatin C), CRP (C-reactive protein), TG (Triglyceride), TC (Total Cholesterol), HDL-C, LDL-C (Low density lipoprotein cholesterol), apoA-I, apoB (Apolipoprotein B), apoE (Apolipoprotein E) and Lp(a) (Lipoprotein (a)) were all measured by Beckman Coulter AU5431.

Statistical analysis

Patients with an estimated glomerular filtration rate(eGFR) lower than 90 ml/min·1.73 m² were defined as having renal insufficiency. All data were collected directly from medical records, and blood samples were collected within 24 h after admission. The Gensini scoring system was used to evaluate coronary angiography, interpreted by 2 experienced coronary angiography operators. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used to estimate the glomerular filtration rate. HDL-C/apoA-I was used to represent HDL particle size.

SPSS 20.0 was used for statistical analysis. Descriptive findings are presented as the mean and standard deviation (Mean ± SD), proportions (%) or interquartile range (IQR 25–75%). Data comparison between two groups was performed by the standard Student’s t test; comparisons between multiple groups were performed by one-way ANOVA. For counting data, the chi-square test was performed. Pearson’s correlation test was performed to analyze the association between eGFR and HDL-C/apoA-I in patients with coronary heart disease. Univariate logistic regression analysis was used to explore the association between HDL-C/apoA-I and risk for the occurrence of coronary heart disease. All p values were 2-tailed.

Results

Baseline characteristics and lipid profiles between patients with and without coronary heart disease

A total of 419 coronary heart disease patients and 105 non-coronary heart disease patients were included in our study. As shown in Table 1, patients with coronary heart disease tended to be smokers (50.12% vs. 36.19%, $P=0.008$). HDL-C and apoA-I levels both decreased significantly in patients with coronary heart disease (0.96 ± 0.01 vs. 1.09 ± 0.03, $P<0.001$ and 1.12 ± 0.01 vs. 1.18 ± 0.02, $P<0.001$, respectively), along with HDL-C/apoA-I (0.85 ± 0.13 vs. 0.92 ± 0.20, $P=0.005$), while Lp(a)
levels were shown to increase in coronary heart disease patients (0.31 ± 0.01 vs. 0.25 ± 0.02, P = 0.001).

Lipid profiles and gensini scores in patients with coronary heart disease, stratified by eGFR
As shown in Table 2, in patients with coronary heart disease, 227 patients had decreased eGFR (eGFR < 90 ml/min·1.73 m²). Both HDL-C/apoA-I levels and HDL-C levels were notably higher in patients with kidney insufficiency (0.83 ± 0.13 and 0.87 ± 0.11, P = 0.005 and 0.93 ± 0.02 and 0.98 ± 0.02, P = 0.024). Additionally, patients were grouped by chronic kidney disease categories, and between-group analysis revealed that HDL-C/apoA-I increased as eGFR declined, and significance was presented in patients with moderately reduced kidney function (eGFR < 60 ml/min·1.73 m²; P < 0.001), as shown in Table 3 and Fig. 1. Finally, Pearson’s correlation test also confirmed an inverse correlation between eGFR and HDL-C/apoA-I levels in coronary heart disease patients, as shown in Fig. 2 (r = -0.166, P = 0.001).

HDL-C/apoA-I in patients with coronary heart disease stratified by gensini scores
Coronary heart disease patients with decreased eGFR were grouped by the median Gensini score, and HDL-C/apoA-I was compared between them (Table 4). In patients with more severe coronary artery stenosis (n = 112), HDL-C/apoA-I levels were presented to be decreasing, but no statistical significance was observed (P = 0.875) between patients with different severities of stenosis. Thus, the same method was applied in all enrolled subjects and coronary heart disease patients without kidney insufficiency, and in both groups, HDL-C/apoA-I levels increased significantly higher with lower Gensini scores (0.849 ± 0.127 and 0.877 ± 0.177, respectively, in all enrolled patients, P = 0.044; 0.816 ± 0.133 and 0.849 ± 0.129, respectively, in coronary heart disease patients without kidney insufficiency, P = 0.007).

Association of HDL-C/apoA-I and the occurrence of coronary heart disease
To analyze the association of HDL-C/apoA-I with the occurrence of coronary heart disease in different groups, HDL-C/apoA-I was stratified by median with the higher group as a reference, and then logistic regression analysis was applied in patients with normal kidney function and patients with declined eGFR (Table 5). Regardless of kidney function, higher HDL-C/apoA-I was associated with a lower risk for coronary heart disease (OR 0.378 and OR 0.349, P < 0.05).

Table 1: Baseline characteristics and lipid profiles in patients with and without coronary heart disease

|                        | Coronary heart disease (n = 419) | Noncoronary heart disease (n = 105) | P value |
|------------------------|----------------------------------|-------------------------------------|---------|
| eGFR (ml/min·1.73 m²)  | 84.88 ± 24.61                    | 79.88 ± 30.356                     | 0.105   |
| Sex (male/female)      | 328/91                           | 77/28                              | 0.170   |
| Age (years)            | 58.72 ± 11.02                    | 57.16 ± 12.67                      | 0.26    |
| BMI (kg/m²)            | 24.34 ± 0.24                     | 24.48 ± 0.47                       | 0.777   |
| Smoking (%)            | 50.12                            | 36.19                              | 0.008   |
| Hypertension (%)       | 56.56                            | 62.86                              | 0.270   |
| Diabetes (%)           | 24.10                            | 20.00                              | 0.439   |
| Systolic BP when Admitted (mmHg) | 134.18 ± 37.24                    | 133.05 ± 24.68                     | 0.768   |
| Diastolic BP when Admitted (mmHg) | 79.89 ± 13.72                    | 80.74 ± 14.97                      | 0.574   |
| CR (mmol/L)            | 90.47 ± 31.53                    | 95.64 ± 40.00                      | 0.157   |
| Cys-C (mmol/L)         | 1.27 ± 0.07                      | 1.10 ± 0.03                        | 0.513   |
| CRP (ng/L)             | 16.51 ± 1.65                     | 15.07 ± 2.89                       | 0.681   |
| TG (mmol/L)            | 1.79 ± 0.05                      | 1.63 ± 0.10                        | 0.195   |
| TC (mmol/L)            | 4.62 ± 0.06                      | 4.64 ± 0.12                        | 0.838   |
| HDL-C (mmol/L)         | 0.96 ± 0.01                      | 1.09 ± 0.03                        | 0.000   |
| LDL-C (mmol/L)         | 2.93 ± 0.04                      | 2.92 ± 0.09                        | 0.905   |
| apoA-I (g/L)           | 1.12 ± 0.01                      | 1.18 ± 0.02                        | 0.001   |
| apoB (g/L)             | 1.06 ± 0.10                      | 0.96 ± 0.02                        | 0.615   |
| Lp(a) (g/L)            | 0.31 ± 0.01                      | 0.25 ± 0.02                        | 0.012   |
| apoE (mg/L)            | 46.64 ± 0.80                     | 46.27 ± 1.48                       | 0.835   |
| HDL-C/apoA-I           | 0.85 ± 0.13                      | 0.92 ± 0.20                        | 0.005   |

BMI, Body mass index; BP, Blood Pressure
### Table 2  Baseline characteristics, lipid profiles and gensini scores in coronary heart disease patients with normal kidney function and kidney insufficiency

|                          | Normal Kidney Function (n = 192) | Renal insufficiency (n = 227) | P value |
|--------------------------|----------------------------------|-------------------------------|---------|
| eGFR (ml/min-1.73 m²)    | 106.30 ± 17.00                   | 67.81 ± 14.14                 | 0.000   |
| Sex(Male/Female)         | 138/54                           | 190/37                        | 0.033   |
| Age                      | 57.72 ± 9.71                     | 59.60 ± 12.00                 | 0.038   |
| BMI (kg/m²)              | 23.91 ± 0.33                     | 24.56 ± 0.32                  | 0.165   |
| Smoking (%)              | 53.14                            | 47.14                         | 0.240   |
| Hypertension (%)         | 45.31                            | 58.15                         | 0.490   |
| Diabetes (%)             | 28.65                            | 20.26                         | 0.052   |
| Systolic BP when Admitted (mmHg) | 133.54 ± 21.77                  | 134.72 ± 46.56                | 0.747   |
| Diastolic BP when Admitted (mmHg) | 79.83 ± 13.40                  | 79.93 ± 14.00                 | 0.943   |
| CR (ч mol/L)             | 71.93 ± 11.41                    | 106.15 ± 34.49                | 0.000   |
| Cys-C (mmol/L)           | 1.06 ± 0.03                      | 1.43 ± 0.13                   | 0.014   |
| CRP (mg/L)               | 16.26 ± 2.59                     | 16.72 ± 2.11                  | 0.890   |
| TG (mmol/L)              | 1.82 ± 0.08                      | 1.76 ± 0.07                   | 0.594   |
| TC (mmol/L)              | 4.51 ± 0.09                      | 4.71 ± 0.08                   | 0.074   |
| HDL-C (mmol/L)           | 0.93 ± 0.02                      | 0.98 ± 0.02                   | 0.024   |
| LDL-C (mmol/L)           | 2.86 ± 0.07                      | 2.99 ± 0.06                   | 0.122   |
| apoA-I (g/L)             | 1.11 ± 0.01                      | 1.13 ± 0.01                   | 0.415   |
| apoB (g/L)               | 1.15 ± 0.22                      | 0.98 ± 0.02                   | 0.386   |
| Lp(a) (g/L)              | 0.29 ± 0.02                      | 0.33 ± 0.02                   | 0.157   |
| apoe (mg/L)              | 47.01 ± 1.24                     | 46.32 ± 1.04                  | 0.665   |
| HDL-C/apoA-I             | 0.83 ± 0.13                      | 0.87 ± 0.11                   | 0.005   |
| Gensini Scores           | 56.40 ± 3.11                     | 59.11 ± 3.09                  | 0.539   |

### Table 3  Baseline characteristics, lipid profiles and gensini scores in coronary heart disease patients stratified by chronic kidney disease categories

|                          | Normal Kidney Function (n = 192) | Normal Kidney Function (n = 192) | Renal insufficiency (n = 227) | P value |
|--------------------------|----------------------------------|----------------------------------|-------------------------------|---------|
| eGFR (ml/min-1.73 m²)    | 106.30 ± 17.00                   | 67.81 ± 14.14                   | 50.26 ± 8.76                   | 0.000   |
| Sex(Male/Female)         | 138/54                           | 190/37                          | 55/12                         | 0.013   |
| Age                      | 57.72 ± 9.71                     | 59.60 ± 12.00                   | 1.73 ± 0.13                   | 0.832   |
| CR (ч mol/L)             | 71.93 ± 11.42                    | 93.30 ± 14.56                   | 136.82 ± 46.9                 | 0.000   |
| TG (mmol/L)              | 1.82 ± 0.08                      | 1.78 ± 0.08                     | 62.17 ± 10.64                 | 0.262   |
| TC (mmol/L)              | 4.51 ± 0.09                      | 4.74 ± 0.10                     | 4.65 ± 0.12                   | 0.175   |
| HDL-C (mmol/L)           | 0.93 ± 0.02                      | 0.96 ± 0.02                     | 1.03 ± 0.03                   | 0.014   |
| LDL-C (mmol/L)           | 2.86 ± 0.07                      | 3.03 ± 0.07                     | 2.91 ± 0.10                   | 0.203   |
| apoA-I (g/L)             | 1.11 ± 0.01                      | 1.13 ± 0.01                     | 1.11 ± 0.02                   | 0.713   |
| apoB (g/L)               | 1.15 ± 0.22                      | 0.99 ± 0.02                     | 0.95 ± 0.03                   | 0.679   |
| Lp(a) (g/L)              | 0.29 ± 0.02                      | 0.33 ± 0.03                     | 0.33 ± 0.04                   | 0.367   |
| apoe (mg/L)              | 47.01 ± 1.24                     | 46.33 ± 1.24                    | 46.28 ± 1.93                  | 0.910   |
| HDL-C/apoA-I             | 0.83 ± 0.13                      | 0.85 ± 0.11                     | 0.90 ± 0.13                   | 0.000   |
| Gensini Scores           | 56.40 ± 3.11                     | 57.74 ± 3.49                    | 62.40 ± 6.34                  | 0.644   |

A indicates a significant difference between patients with normal kidney function and patients with mildly reduced kidney function (eGFR < 90 ml/min-1.73 m²); B indicates a significant difference between patients with normal kidney function and patients with moderately reduced kidney function (eGFR60 ml/min-1.73 m²); C indicates a significant difference between patients with mildly reduced kidney function and patients with moderately reduced kidney function.
Dyslipidemia is an independent risk factor for cardiovascular disease, which is the leading cause of death in chronic kidney disease patients [9]. Renal deficiency has also been identified as an independent risk factor for coronary heart disease, as kidney deficiency may contribute to the development of atherosclerosis and is related to premature cardiovascular events [10]. Stack et al. have reported that patients on hemodialysis had a 38% higher incidence of cardiovascular diseases, and other studies have also reported that for every 10 mL/(min·1.73 m²) reduction in eGFR, the occurrence of cardiovascular diseases can increase by 19% [12].

HDL has been widely acknowledged as a protective factor in both cardiovascular disease and chronic kidney disease patients, as it acts as an acceptor of cellular cholesterol and initiates reverse cholesterol transport by transferring peripheral cholesterol back to the liver. Lower plasma HDL-C levels are known to be associated with an increased occurrence of major cardiovascular events. The Framingham study has reported that in a healthy population, for every 1 mg/dl increase in HDL-C levels, the incidence of coronary heart disease was reduced by 2% to 3% [1]. However, in recent years, studies aimed at elevating HDL-C levels have successively failed to reduce cardiovascular events, and it has been reported that high HDL-C levels are not always correlated with reduced cardiovascular death [13]. Therefore, an increasing number of studies have shifted their focus for coronary heart disease, as kidney deficiency may contribute to the development of atherosclerosis and is related to premature cardiovascular events [10].

Fig. 1 HDL-C/apoA-I stratified by chronic kidney disease categories in patients with coronary heart disease. a Indicates a significant difference between patients with normal kidney function and patients with mildly reduced kidney function (60 mL/min·1.73 m² ≤ eGFR < 90 mL/min·1.73 m²); b indicates a significant difference between patients with normal kidney function and patients with moderately reduced kidney function (eGFR ≤ 60 mL/min·1.73 m²); c indicates a significant difference between patients with mildly reduced kidney function and patients with moderately reduced kidney function.

Fig. 2 Correlation of eGFR and HDL-C/apoA-I in coronary heart disease patients.

**Table 4** HDL-C/apoA-I in patients with coronary heart disease stratified by Gensini scores

| Group                                      | HDL-C/apoA-I | P value |
|--------------------------------------------|--------------|---------|
| All enrolled patients                      |              |         |
| High Gensini scores                        | 0.849 ± 0.127 | 0.044   |
| Low Gensini scores                         | 0.877 ± 0.177 |         |
| Coronary heart disease patient with kidney insufficiency |              |         |
| High Gensini scores                        | 0.866 ± 0.113 | 0.875   |
| Low Gensini scores                         | 0.869 ± 0.112 |         |
| Coronary heart disease patient without kidney insufficiency |              |         |
| High Gensini scores                        | 0.816 ± 0.133 | 0.007   |
| Low Gensini scores                         | 0.849 ± 0.129 |         |

**Table 5** Association of HDL-C/apoA-I with the occurrence of coronary heart disease

| Group                                      | OR    | 95% CI      | P value |
|--------------------------------------------|-------|-------------|---------|
| Patients without kidney insufficiency      |       |             |         |
| Low HDL-C/apoA-I                           | 1     |             |         |
| High HDL-C/apoA-I                          | 0.478 | 0.230–0.994 | 0.048   |
| Patients with kidney insufficiency         |       |             |         |
| Low HDL-C/apoA-I                           | 1     |             |         |
| High HDL-C/apoA-I                          | 0.349 | 0.423–1.258 | 0.000   |
from the HDL-C level to HDL function and HDL particle size.

HDL is mainly composed of larger HDL2 and smaller HDL3. In the process of reverse cholesterol transport (RCT), small, flat pre-β-HDL gradually matures into large, spherical HDL2; thus, larger HDL particles are generally considered to be more mature and have greater cardiovascular protective effects [14]. In cardiovascular disease, the subpopulations of HDL may be altered due to a disrupted or even hindered RCT process [15]. Both HDL dysfunction and altered HDL distribution are likely to be related to oxidative stress and inflammation [16, 17], which also contribute to endothelial dysfunction and account for their association with the acceleration of chronic kidney disease.

In our study, lower HDL-C/apoA1 was shown to be closely related to coronary artery stenosis in coronary heart disease patients with normal kidney function; however, in coronary heart disease patients with a moderately decreased eGFR, HDL-C/apoA-I grew larger, and the original association with coronary artery stenosis was also lost. Since HDL-C/apoA-I was used to represent HDL particle sizes in our study, our results demonstrated the same association between HDL particle sizes and coronary artery stenosis. Similar phenomena have been reported in several studies [18–20]. In the past, it was believed that lipoproteins cannot pass the glomerular filtration barrier. Despite HDL being the smallest of all lipoproteins, containing the least lipids but the most protein, there is no evidence of intact HDL particles filtering through the glomerular filtration barrier. However, subfractions of HDL particles metabolize separately [18]. Albumin, which has a molecular weight of 66.5 kD, has already been proven to cross the glomerular filtration barrier; thus, apoA-I, weighted 28 kD, and pre-β-HDL, weighted 60 to 85 kD, can both cross a normally functioning glomerular filtration barrier theoretically, while larger subfractions are likely to be filtered in individuals with injured kidney function [21]. Therefore, it is reasonable to assume that increased HDL particle size in chronic kidney disease patients is a result of the loss of smaller HDL particles through the glomerular filtration barrier.

Our results also reported the loss of association between HDL particle size and Gensini score in the context of comorbidity of coronary heart disease with renal insufficiency. In our study, renal deficiency was defined as an eGFR < 90 mL/(min·1.73 m²), as renal damage and related dyslipidemia have already started in early stages of chronic kidney disease [22]. Chronic kidney disease is known to be an independent risk factor for cardiovascular disease, so it is reasonable to assume that with renal insufficiency in the picture, the size shifting of HDL particles, which reflects only an imbalance in HDL metabolism, is no longer a strong predictor of the severity of coronary heart disease [23, 24]. In coronary heart patients with renal insufficiency, the protective effects of larger HDL particles may be weakened; thus, lipid-targeting therapy may not be as essential in these patients.

Our study explored the still-debated effect of renal function on HDL particle size in patients with coronary artery disease using HDL-C/apoA-I to represent HDL particle size. However, as a single-center retrospective study, the sample size was relatively small, and further confirmation of our theory would require analysis of urine protein profiles. Additionally, HDL-C/apoA-I represents only the average size of HDL particles; thus, HDL subfraction analysis is still needed if the specific alterations in HDL subpopulations in chronic kidney disease patients are to be explored in the future.

**Conclusion**

In our study, lower HDL-C/apoA1 was shown to be associated with more severe coronary artery stenosis in coronary heart disease patients with normal kidney function. However, in coronary heart disease patients with renal insufficiency, an inverse correlation of eGFR with HDL-C/apoA1 was found as eGFR declined to 60 ml/min·1.73 m², accompanied by a loss of association between HDL-C/apoA1 and coronary artery stenosis.

**Abbreviations**

HDL: High-density lipoprotein; HDL-C: High-density lipoprotein cholesterol; apoA-I: Apolipoprotein A-I; eGFR: Estimated glomerular filtration rate; ESRD: End-stage kidney disease; NMRI: Nuclear magnetic resonance imaging; CKD-EPI: The Chronic Kidney Disease Epidemiology Collaboration; BMI: Body mass index; BP: Blood Pressure; CR: Creatinine; Cys-C: Cystatin C; CRP: C-reactive protein; TG: Triglyceride; TC: Total Cholesterol; Lp(a): Lipoprotein (a); apoE: Apolipoprotein E.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

LJ analyzed and interpreted the patient data and was a major contributor in writing the manuscript. XY, ZK, LD, MY and RJ interpreted the data; ZB, LL and LJ analyzed and interpreted the patient data and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by Guangdong Basic and Applied Basic Research Foundation (2019A1515010666), the Clinical Research Startup Program of Southern Medical University by High-level Construction Funding of Guangdong Provincial Department of Education (LC2016PY002), and the Clinical Research Foundation of Nanfang Hospital (2018CR01). The sponsors had no role in the study design, data collection and analysis, decision to publish or the reparation of the manuscript.

**Availability of data and materials**

The data that support the findings of this study are available from Southern Medical University Nanfang Hospital but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon request.
reasonable request and with permission of Southern Medical University Nanfang Hospital.

Declarations

Ethics approval and consent to participate

Study was approved by and carried out in accordance with institutional review board of Nanfang Hospital of Southern Medical University, and our protocol was performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from participants/legal guardians of participants involved in the study. Availability of data and materials was not applicable for the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 11 June 2021   Accepted: 25 October 2021

Published online: 12 November 2021

References

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Framingham Study Am J Med. 1977;62(5):707–14. https://doi.org/10.1016/0002-9343(77)90874-9.

2. Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122(1):106–12. https://doi.org/10.1161/CIRCRESAHA.117.311978.

3. Armitage J, Holmes MV, Preiss D. Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week. J Am Coll Cardiol. 2019;73(4):477–87. https://doi.org/10.1016/j.jacc.2018.10.072.

4. Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR. Cholesteryl ester transfer protein: an enigmatic pharmacology—antagonists and agonists. Atherosclerosis. 2018;278:286–98. https://doi.org/10.1016/j.atherosclerosis.2018.09.035.

5. Matsushita K, Ballew SH, Coresh J. Cardiovascular risk prediction in people with chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(6):518–23. https://doi.org/10.1097/MNH.0000000000000265.

6. Coimbra S, Reis F, Valente MJ, et al. Subpopulations of high-density lipoprotein: friends or foes in cardiovascular disease risk in chronic kidney disease? BioMedicines. 2021;9(5):554. https://doi.org/10.3390/biomedicines9050554.

7. Dong J, Guo H, Yang R, et al. Serum LDL- and HDL-cholesterol determined by ultracentrifugation and HPLC. J Lipid Res. 2011;52(2):383–8. https://doi.org/10.1194/jlr.D001479.

8. Mazer NA, Giuliani F, Paynter NR, Jordan P, Mora S. A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women’s Health Study. Clin Chem. 2013;59(6):949–58. https://doi.org/10.1373/clinchem.2012.196949.

9. Lamprea-Montalegre JA, Staplin N, Herrington WG, et al. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin J Am Soc Nephrol. 2020;15(1):47–60. https://doi.org/10.2215/CJN.07320619.

10. Vallianou NG, Mitesh S, Gkogkou A, Geladani E. Chronic kidney disease and cardiovascular disease: is there any relationship? Curr Cardiol Rev. 2019;15(1):55–63. https://doi.org/10.2147/1573403X14666180711124825.

11. Lamprea-Montalegre JA, McClelland RL, Otvos JL, et al. Association of high-density lipoprotein particles and high-density lipoprotein apolipoprotein C-III content with cardiovascular disease risk according to kidney function: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2019;8(24):. e013713. https://doi.org/10.1161/JAHA.119.013713.

12. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 2001;12(7):156–23. https://doi.org/10.1681/ASN.2001121566.

13. Hillege HL, Gibbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102(2):203–10. https://doi.org/10.1161/01.cir.102.2.203.

14. Rysz J, Gluba-Brzózka A, Rysz-Górzyńska M, Franczyk B. The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease. Int J Mol Sci. 2020;21(2):601. https://doi.org/10.3390/ijms21020601.

15. Pappa E, Eliafu MS, Kostara C, Bairaktari E, Tsimihodimos VK. Cardioprotective properties of HDL: structural and functional considerations. Curr Med Chem. 2020;27(18):2964–78. https://doi.org/10.2174/092986732766619200114321.

16. Bae IC, Hán JM, Kwon S, et al. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort. Atherosclerosis. 2016;251:170–6. https://doi.org/10.1016/j.atherosclerosis.2016.06.029.

17. Xi D, Zhao J, Guo K, et al. Serum amyloid P component therapeutically attenuates atherosclerosis in mice via its effects on macrophages. Theranostics. 2018;8(12):3214–23. https://doi.org/10.7150/thno.22704.

18. Hu J, Xi D, Zhao J, et al. High-density lipoprotein and inflammation and its significance to atherosclerosis. Am J Med Sci. 2016;352(4):408–15. https://doi.org/10.1016/j.amjmed.2016.06.014.

19. Soto-Miranda E, Carreón-Torres E, Lorenzo K, et al. Shift of high-density lipoprotein size distribution toward large particles in patients with proteinuria. Clin Chim Acta. 2012;414:241–5. https://doi.org/10.1016/j.cca.2012.09.028.

20. Rysz-Górzyńska M, Gluba-Brzózka A, Banach M. High-density lipoprotein and low-density lipoprotein subfractions in patients with chronic kidney disease. Curr Vasc Pharmacol. 2017;15(2):144–51. https://doi.org/10.2174/1570414X15161146661600309032.

21. López-Olmos V, Carreón-Torres E, Luna-Luna M, et al. Increased HDL size and enhanced apo A-I catabolic rates are associated with doxorubicin-induced proteinuria in New Zealand White Rabbits. LipoR. 2016;51(3):311–20. https://doi.org/10.1007/s11745-016-4120-6.

22. Wahl P, Ducasa GM, Fornoni A. Systemic and renal lipids in kidney disease development and progression. Am J Physiol Renal Physiol. 2016;310(6):F433–45. https://doi.org/10.1152/ajprenal.00375.2015.

23. Strazzella A, Ossoli A, Galabreis L. High-density lipoproteins and the kidney. Cells. 2021;10(4):764. https://doi.org/10.3390/cells10040764.

24. Gluba-Brzózka A, Franczyk B, Banach M, Rysz-Górzyńska M. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients? Int Urol Nephrol. 2017;49(1):155–64. https://doi.org/10.1007/s11255-016-1466-x.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.